Sionna Therapeutics, Inc.

NASDAQ: SION · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0002036042Reports USD

#1 of 1,420 Healthcare companies by revenue

EA Score

——

FH 65DQ —GM —SS 49

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$75.3M

Employees

as of 2026-08-09

Market cap

$2.3B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$75.3M-$75.3M2025

Operating income-$89.0M-$89.0M2025

Total assets$326.0M$326.0M2025

Liabilities$19.1M$19.1M2025

Equity$306.8M$306.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Sionna Therapeutics, Inc.’s financial profile?

Sionna Therapeutics, Inc. earned -$75.3M in FY2025 net income.

Peers · Healthcare

Trevi Therapeutics, Inc.——Mineralys Therapeutics, Inc.——Vera Therapeutics, Inc.——Biohaven Ltd.——Kailera Therapeutics, Inc.——Rapport Therapeutics, Inc. Common Stock——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B63C Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Symbotic Inc.$2.2B48D

Key facts

CEOMichael Cloonan

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: SION

Employees59

IPO date2025-02-07

Latest filings

8-K2026-08-10 10-Q2026-08-06 8-K2026-08-06 8-K2026-06-18 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-27 8-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.